Combined anticancer therapy with imidazoacridinone analogue C‐1305 and paclitaxel in human lung and colon cancer xenografts—Modulation of tumour angiogenesis

Marta Świtalska; Beata Filip‐Psurska; Magdalena Milczarek; Mateusz Psurski; Adrianna Moszyńska; Aleksandra Dąbrowska; Małgorzata Gawrońska; Karol Krzymiński; Maciej Bagiński; Rafał Bartoszewski; Joanna Wietrzyk

doi:10.1111/jcmm.17430

Combined anticancer therapy with imidazoacridinone analogue C‐1305 and paclitaxel in human lung and colon cancer xenografts—Modulation of tumour angiogenesis

Abstrakt

The acridanone derivative 5-dimethylaminopropylamino- 8- hydroxytriazoloacridinone (C-1305) has been described as a potent inhibitor of cancer cell growth. Its mechanism of action in in vitro conditions was attributed, among others, to its ability to bind and stabilize the microtubule network and subsequently exhibit its tumour- suppressive effects in synergy with paclitaxel (PTX). Therefore, the objective of the present study was to analyse the effects of the combined treatment of C-1305 and PTX in vivo. In addition, considering the results of previous genomic analyses, par-ticular attention was given to the effects of this treatment on tumour angiogenesis. Treatment with C-1305 revealed antitumor effect in A549 lung cancer cells, and com-bined treatment with PTX showed tendency to anticancer activity in HCT116 colon cancer xenografts. It also improved tumour blood perfusion in both tumour models. The plasma level of CCL2 was increased and that of PDGF was decreased after com-bined treatment with C-1305 and PTX. The experimental results showed that the levels of FGF1, TGF-β and Ang-4 decreased, whereas the levels of ERK1/2 and Akt phosphorylation increased in HCT116 tumour tissue following combined treatment with both drugs. The results of in vitro capillary- like structure formation assay dem-onstrated the inhibiting effect of C-1305 on this process. Although previous in vitro and in vivo studies suggested a positive effect of C-1305 on cancer cells, combined treatment of HCT116 human colon and A549 lung cancer cells with both PTX and C- 1305 in vivo showed that the antitumor activity was restricted and associated with the modulation of tumour angiogenesis.

Cytowania

5

CrossRef
0

Web of Science
5

Scopus

Autorzy (11)

Marta Świtalska
Beata Filip‐Psurska
Magdalena Milczarek
Mateusz Psurski
Adrianna Moszyńska
Aleksandra Dąbrowska
Małgorzata Gawrońska
Karol Krzymiński
Maciej Bagiński prof. dr hab. inż.
Rafał Bartoszewski
Joanna Wietrzyk

Cytuj jako

Pełna treść

pobierz publikację

pobrano 42 razy

Wersja publikacji: Accepted albo Published Version
DOI:: Cyfrowy identyfikator dokumentu elektronicznego (otwiera się w nowej karcie) 10.1111/jcmm.17430
Licencja: otwiera się w nowej karcie

Słowa kluczowe

Informacje szczegółowe

Kategoria:

Publikacja w czasopiśmie

Typ:

artykuły w czasopismach

Opublikowano w:

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE nr 26, strony 3950 - 3964,
ISSN: 1582-1838

Język:

angielski

Rok wydania:

2022

Opis bibliograficzny:

Świtalska M., Filip‐psurska B., Milczarek M., Psurski M., Moszyńska A., Dąbrowska A., Gawrońska M., Krzymiński K., Bagiński M., Bartoszewski R., Wietrzyk J.: Combined anticancer therapy with imidazoacridinone analogue C‐1305 and paclitaxel in human lung and colon cancer xenografts—Modulation of tumour angiogenesis// JOURNAL OF CELLULAR AND MOLECULAR MEDICINE -Vol. 26,iss. 14 (2022), s.3950-3964

DOI: